Treatment of bone metastases in breast cancer patients

被引:0
作者
Pawlak, Wojciech Z. [1 ]
Wawrocka-Pawlak, Marlena [2 ]
机构
[1] NZOZ Grupowa Praktyka Onkologiczna, Oddzial Chemioterapii Dziennej, Olsztyn, Poland
[2] Uniwersytet Warminsko Mazurski, Zaklad Pielegniarstwa, Olsztyn, Poland
来源
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2006年 / 10卷 / 08期
关键词
breast cancer; bone metastases; radiotherapy; bisphosphonates;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone metastases are a major problem in the clinical management of patients with breast cancer. With prolongation of survival, the challenge is to improve the quality of the patient's remaining life. The treatment of metastatic bone disease requires a multidisciplinary approach that addresses systemic and focal disease. The complex nature of metastatic disease requires the combined efforts of a team of clinical, radiation, and orthopaedic oncologists. Prevention and treatment of skeletal complications requires early detection and aggressive management. Focal complications are best treated with both surgery and radiotherapy. Systemic disease and complications are best addressed with hormonal therapy, chemotherapy, and bisphosphonate therapy. External-beam radiotherapy has become a mainstay in the palliative treatment of metastatic bone disease. The indications for radiotherapy are the relief of pain and the control of localized disease. Bisphosphonates, as inhibitors of osteoclast activity, are very effective in the prevention of skeletal complications and hypercalcaemia.
引用
收藏
页码:401 / 407
页数:7
相关论文
共 53 条
[1]   Radiation therapy in the management of symptomatic bone metastases: The effect of total dose and histology on pain relief and response duration [J].
Arcangeli, G ;
Giovinazzo, G ;
Saracino, B ;
D'Angelo, L ;
Giannarelli, D ;
Arcangeli, G ;
Micheli, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (05) :1119-1126
[2]   Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates [J].
Berruti, A ;
Dogliotti, L ;
Tucci, M ;
Tarabuzzi, R ;
Fontana, D ;
Angeli, A .
JOURNAL OF UROLOGY, 2001, 166 (06) :2023-2031
[3]  
Blamey R, 1999, EUR J SURG ONCOL, V25, P3
[4]  
BLITZER PH, 1985, CANCER-AM CANCER SOC, V55, P1468, DOI 10.1002/1097-0142(19850401)55:7<1468::AID-CNCR2820550708>3.0.CO
[5]  
2-M
[6]  
DIJKSTRA S, 1994, EUR J SURG, V160, P535
[7]   A population-based study of surgery for spinal metastases [J].
Finkelstein, JA ;
Zaveri, G ;
Wai, E ;
Vidmar, M ;
Kreder, H ;
Chow, E .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2003, 85B (07) :1045-1050
[8]   DIPHOSPHONATES INHIBIT HYDROXYAPATITE DISSOLUTION IN VITRO AND BONE RESORPTION IN TISSUE CULTURE AND IN VIVO [J].
FLEISCH, H ;
RUSSELL, RGG ;
FRANCIS, MD .
SCIENCE, 1969, 165 (3899) :1262-&
[9]   EFFECT OF PYROPHOSPHATE ON HYDROXYAPATITE AND ITS IMPLICATIONS IN CALCIUM HOMEOSTASIS [J].
FLEISCH, H ;
RUSSEL, RGG ;
STRAUMANN, F .
NATURE, 1966, 212 (5065) :901-+
[10]   Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients [J].
Fourney, DR ;
Schomer, DF ;
Nader, R ;
Chlan-Fourney, J ;
Suki, D ;
Ahrar, K ;
Rhines, LD ;
Gokaslan, ZL .
JOURNAL OF NEUROSURGERY, 2003, 98 (01) :21-30